Notice Regarding the Recognition of Non-Operating Income and Extraordinary Gains
Medrx Co.,Ltd. (filing company)
Time deposits held at the head office, the 10th Series of Stock Acquisition Rights (issued on 1 March 2016), and stock acquisition rights held by employees who left the company
The interest received was mainly interest earned on time deposits held at the head office. The gain on reversal of stock acquisition rights resulted from the expiration of the exercise period for the 10th Series of Stock Acquisition Rights and the expiration of stock acquisition rights held by employees who left the company.
¥1 million in interest received (non-operating income) and ¥9 million in gain on reversal of stock acquisition rights (extraordinary gain)
Cumulative consolidated period for the first quarter of the fiscal year ending December 2026 (1 January 2026–31 March 2026)
For the impact on the Medrx Co.,Ltd. Group's results for the first quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (15 May 2026). Information regarding revisions to earnings forecasts: Not disclosed.
| Item | Details |
|---|---|
| Event name | Notice Regarding the Recognition of Non-Operating Income and Extraordinary Gains |
| Date of occurrence | 1 January 2026 to 31 March 2026 (period covered by the accounting entries) |
| Subject Entity | Medrx Co.,Ltd. (filing company) |
| Target Locations / Products | Time deposits held at the head office, the 10th Series of Stock Acquisition Rights (issued on 1 March 2016), and stock acquisition rights held by employees who left the company |
| Cause | The interest received was mainly interest earned on time deposits held at the head office. The gain on reversal of stock acquisition rights resulted from the expiration of the exercise period for the 10th Series of Stock Acquisition Rights and the expiration of stock acquisition rights held by employees who left the company. |
| Amount of Impact on Business Performance | ¥1 million in interest received (non-operating income) and ¥9 million in gain on reversal of stock acquisition rights (extraordinary gain) |
| Accounting period in which recognized | Cumulative consolidated period for the first quarter of the fiscal year ending December 2026 (1 January 2026–31 March 2026) |
| Impact on Earnings Forecast | For the impact on the Medrx Co.,Ltd. Group's results for the first quarter of the fiscal year ending December 2026, please refer to the "Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)" released today (15 May 2026). Information regarding revisions to earnings forecasts: Not disclosed. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The interest received was mainly interest earned on time deposits held at the head office. The gain on reversal of stock acquisition rights resulted from the expiration of the exercise period for the 10th Series of Stock Acquisition Rights and the expiration of stock acquisition rights held by employees who left the company.